Day: November 27, 2025

VANCOUVER, British Columbia, Nov. 26, 2025 (GLOBE NEWSWIRE) — Fortuna Mining Corp. (NYSE: FSM | TSX: FVI) is pleased to announce that, in accordance with National Instrument 43-101 –  Standards of Disclosure for Mineral Projects, it has filed the technical report entitled “Diamba Sud Gold Project, Kédougou Region, Senegal”, with an effective date of October 15, 2025  (the “Technical Report”), supporting the results of the Preliminary Economic Assessment (PEA) previously announced in Fortuna’s news release dated October 15, 2025. The Technical Report is available on the Company’s website, on SEDAR+ and on EDGAR under the Company’s profile.   About Fortuna Mining Corp. Fortuna Mining Corp. is a Canadian precious metals mining company with three operating mines and a portfolio of exploration projects in Argentina, Côte d’Ivoire,...

TOKYO, JAPAN, Nov. 26, 2025 (GLOBE NEWSWIRE) — Linkage Global Inc (NASDAQ: LGCB) (“Linkage Global” or the “Company”), a cross-border e-commerce integrated services provider headquartered in Japan, is pleased to announce the pricing of a private investment in public equity (the “PIPE”) financing. On November 24, 2025, the Company entered into a securities purchase agreement pursuant to which it will issue and sell an aggregate of 689,655 Class A Ordinary Shares to an investor at a price of US$1.45 per share. The offering will result in total gross proceeds of approximately US$1,000,000 before deducting fees and offering expenses payable by the Company. Subject to customary closing conditions, the PIPE is expected to close on or before December 3, 2025. The securities will be sold in a private...

CALGARY, Alberta, Nov. 26, 2025 (GLOBE NEWSWIRE) — Quorum Information Technologies Inc. (TSX-V: QIS) (“Quorum” or the “Company”) is pleased to announce that its shareholders (the “Quorum Shareholders”) have approved a special resolution to approve a statutory plan of arrangement (the “Arrangement“) under the Business Corporations Act (Alberta) involving Quorum, the Quorum Shareholders, and 2745122 Alberta Inc. (the “Purchaser“), an affiliate of Valsoft Corporation Inc., as more particularly described in the management information circular dated October 22, 2025, which is available on SEDAR+ (www.sedarplus.ca) under Quorum’s issuer profile. Quorum Shareholders representing a total of 58,584,797 Common Shares (the “Quorum Shares“) were present in person or represented by proxy at the special meeting...

 Avante Corp. achieved 10% year-over-year revenue growth in fiscal second quarter ended September 30, 2025, driven by 47% increase in NSSG revenue, and 48% increase in Avante Black revenue.The Company achieved Adjusted EBITDA from continuing operations of $0.58 million in the fiscal second quarter, an increase of 73%, and the second quarter in a row of positive Net Income.The Company maintains a positive outlook for fiscal 2026, with expected organic growth across its services including Avante Black, HALO, Avante Verified, and MAST. TORONTO, Ontario, Nov. 26, 2025 (GLOBE NEWSWIRE) — Avante Corp. (TSX.V: XX) (OTC: ALXXF) (“Avante” or the “Company”) is pleased to announce its financial results representing the three months ended September 30, 2025 (all amounts in Canadian dollars thousands, unless otherwise indicated). Manny...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 27, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology (“ASH”) Annual Meeting taking place on December 6-9, 2025 in Orlando, USA. Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma, will be presented at the ESMO...